Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Grifols S.A. (GRFS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 14,653,317
  • Shares Outstanding, K 682,820
  • Annual Sales, $ 4,482 M
  • Annual Income, $ 603,600 K
  • 36-Month Beta 1.10
  • Price/Sales 3.20
  • Price/Cash Flow 15.72
  • Price/Book 3.48

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.24 +6.23%
on 04/24/17
22.25 -3.37%
on 05/01/17
+1.55 (+7.77%)
since 04/21/17
3-Month
17.24 +24.71%
on 03/14/17
22.25 -3.37%
on 05/01/17
+4.04 (+23.14%)
since 02/22/17
52-Week
14.27 +50.67%
on 10/31/16
22.25 -3.37%
on 05/01/17
+6.66 (+44.88%)
since 05/20/16

Most Recent Stories

More News
Investigational New Drug Application is Now Effective for Babesia Screening in Blood Donations Using Grifols Procleix Panther System in the US

-- Test is designed to detect the presence in whole blood, of the four clinically relevant species of Babesia (B. microti, B. duncani, B. divergens, and B. venatorum), a parasite that can be transmitted...

GRFS : 21.50 (+0.19%)
GRF : 7.68 (+1.32%)
VIVUS (VVUS) Loss Narrower than Expected, Revenues Up Y/Y

VIVUS Inc. (VVUS) reported a loss of 1 cent per share in the first quarter of 2017, which was narrower than a loss of 12 cents in the year-ago period as well as the Zacks Consensus Estimate of a loss of...

VVUS : 1.08 (+3.85%)
GRFS : 21.50 (+0.19%)
INFI : 1.79 (+0.56%)
SNY : 49.16 (-0.30%)
Akebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8%

Akebia Therapeutics, Inc. (AKBA) shares rose almost 6% in the last trading session.

AKBA : 13.93 (-2.25%)
GRFS : 21.50 (+0.19%)
Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View

GlaxoSmithKline plc's (GSK) first quarter results came roughly in line with expectations. Glaxo reported first-quarter 2017 core earnings of 62 cents per American Depositary Share (ADS), in line with...

MYL : 38.64 (+1.85%)
GRFS : 21.50 (+0.19%)
INFI : 1.79 (+0.56%)
GSK : 43.30 (-0.69%)
Celgene (CELG) Tops on Q1 Earnings, Sales Miss, Raises View

Celgene's (CELG) first-quarter results were mixed, with the company beating on earnings but missing on sales.

AGIO : 49.26 (+0.20%)
CELG : 115.71 (-1.04%)
GRFS : 21.50 (+0.19%)
INFI : 1.79 (+0.56%)
AbbVie (ABBV) Presents Positive Data on HCV Combination Drug

AbbVie Inc. (ABBV) announced that data from two phase III studies, EXPEDITION-1 and ENDURANCE-3, evaluating its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P) for all genotypes...

ENTA : 31.87 (-1.88%)
GRFS : 21.50 (+0.19%)
INFI : 1.79 (+0.56%)
ABBV : 65.44 (-0.21%)
Nivalis' (NVLS) Shares Down After Merger Deal with Alpine

The announcement of Nivalis Therapeutics, Inc.'s (NVLS) merger agreement with a privately-held biotechnology company, Alpine Immune Sciences, Inc. failed to excite investors.

CORT : 11.89 (+0.93%)
GRFS : 21.50 (+0.19%)
INFI : 1.79 (+0.56%)
NVLS : 2.40 (+3.45%)
Zacks.com featured highlights: Arbor Realty, Commercial Vehicle Group, Grifols, S.A., Match Group and Xcerra

Zacks.com featured highlights: Arbor Realty, Commercial Vehicle Group, Grifols, S.A., Match Group and Xcerra

ABR : 8.21 (+0.49%)
XCRA : 9.48 (-2.17%)
MTCH : 19.65 (+2.61%)
GRFS : 21.50 (+0.19%)
CVGI : 8.30 (-2.47%)
GENOCEA BIOSCIENCES (GNCA) Catches Eye: Stock Gains 7.1%

GENOCEA BIOSCIENCES, INC. (GNCA) moved big last session, as its shares rose over 7% on the day.

GNCA : 5.87 (-2.49%)
GRFS : 21.50 (+0.19%)
How to Uncover Institutional Buying

How to Uncover Institutional Buying

ABR : 8.21 (+0.49%)
XCRA : 9.48 (-2.17%)
MTCH : 19.65 (+2.61%)
GRFS : 21.50 (+0.19%)
CVGI : 8.30 (-2.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience...

See More

Support & Resistance

2nd Resistance Point 21.73
1st Resistance Point 21.61
Last Price 21.50
1st Support Level 21.39
2nd Support Level 21.29

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.